Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Inhibition of tissue factor-dependent and -independent coagulation by cell surface expression of novel anticoagulant fusion proteins

Chen, Daxin ; Riesbeck, Kristian LU orcid ; Kemball-Cook, Geoffrey ; McVey, John H. ; Tuddenham, Edward G.D. ; Lechler, Robert I. and Dorling, Anthony (1999) In Transplantation 67(3). p.467-474
Abstract

Background. Thrombotic vascular occlusion occurs in disorders of diverse etiology, including atherosclerosis, vasculitis, and disseminated intravascular coagulation. The same process results in hyperacute rejection of renal allografts transplanted into sensitized patients and remains a major problem in experimental xenotransplantation. Methods. We have previously described the design and expression of several genetic constructs encoding novel fusion proteins with anticoagulant properties. They are based on two naturally occurring soluble anticoagulant proteins, human tissue factor pathway inhibitor (hTFPI) and the leech protein hirudin, which act early and late in the clotting cascade, respectively. We report the expression of human... (More)

Background. Thrombotic vascular occlusion occurs in disorders of diverse etiology, including atherosclerosis, vasculitis, and disseminated intravascular coagulation. The same process results in hyperacute rejection of renal allografts transplanted into sensitized patients and remains a major problem in experimental xenotransplantation. Methods. We have previously described the design and expression of several genetic constructs encoding novel fusion proteins with anticoagulant properties. They are based on two naturally occurring soluble anticoagulant proteins, human tissue factor pathway inhibitor (hTFPI) and the leech protein hirudin, which act early and late in the clotting cascade, respectively. We report the expression of human hTFPICD4 on the surface of immortalized porcine endothelial cells (IPEC), and show that it functions across the species divide as evidenced by the binding of membrane-expressed porcine tissue factor (pTF)-human factor VIIa complexes. Results. Using a human plasma recalcification clotting assay, we distinguished between pTF-dependent and pTF-independent fibrin generation, and we have demonstrated that expression of hTFPI-CD4 on IPEC effectively prevented pTF-dependent clotting. Moreover, we show that when hTFPI-CD4 was co-expressed with the hirudin construct, the procoagulant properties of in vitro cultured, activated IPEC were almost completely abolished. Conclusions. These results suggest that these novel anticoagulant molecules may prove useful therapeutic agents for gene therapy or for transgenic expression in animals whose organs may be used for clinical xenotransplantation.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; and
publishing date
type
Contribution to journal
publication status
published
in
Transplantation
volume
67
issue
3
pages
467 - 474
publisher
Lippincott Williams & Wilkins
external identifiers
  • scopus:0033557189
  • pmid:10030296
ISSN
0041-1337
DOI
10.1097/00007890-199902150-00021
language
English
LU publication?
no
id
213a18f9-79c4-4f68-a3ac-74e51fb3ff40
date added to LUP
2019-06-07 15:17:57
date last changed
2024-06-11 15:57:54
@article{213a18f9-79c4-4f68-a3ac-74e51fb3ff40,
  abstract     = {{<p>Background. Thrombotic vascular occlusion occurs in disorders of diverse etiology, including atherosclerosis, vasculitis, and disseminated intravascular coagulation. The same process results in hyperacute rejection of renal allografts transplanted into sensitized patients and remains a major problem in experimental xenotransplantation. Methods. We have previously described the design and expression of several genetic constructs encoding novel fusion proteins with anticoagulant properties. They are based on two naturally occurring soluble anticoagulant proteins, human tissue factor pathway inhibitor (hTFPI) and the leech protein hirudin, which act early and late in the clotting cascade, respectively. We report the expression of human hTFPICD4 on the surface of immortalized porcine endothelial cells (IPEC), and show that it functions across the species divide as evidenced by the binding of membrane-expressed porcine tissue factor (pTF)-human factor VIIa complexes. Results. Using a human plasma recalcification clotting assay, we distinguished between pTF-dependent and pTF-independent fibrin generation, and we have demonstrated that expression of hTFPI-CD4 on IPEC effectively prevented pTF-dependent clotting. Moreover, we show that when hTFPI-CD4 was co-expressed with the hirudin construct, the procoagulant properties of in vitro cultured, activated IPEC were almost completely abolished. Conclusions. These results suggest that these novel anticoagulant molecules may prove useful therapeutic agents for gene therapy or for transgenic expression in animals whose organs may be used for clinical xenotransplantation.</p>}},
  author       = {{Chen, Daxin and Riesbeck, Kristian and Kemball-Cook, Geoffrey and McVey, John H. and Tuddenham, Edward G.D. and Lechler, Robert I. and Dorling, Anthony}},
  issn         = {{0041-1337}},
  language     = {{eng}},
  month        = {{02}},
  number       = {{3}},
  pages        = {{467--474}},
  publisher    = {{Lippincott Williams & Wilkins}},
  series       = {{Transplantation}},
  title        = {{Inhibition of tissue factor-dependent and -independent coagulation by cell surface expression of novel anticoagulant fusion proteins}},
  url          = {{http://dx.doi.org/10.1097/00007890-199902150-00021}},
  doi          = {{10.1097/00007890-199902150-00021}},
  volume       = {{67}},
  year         = {{1999}},
}